Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Has Consensus Target Price of $630.42

Posted by Brenda Bartman on Nov 13th, 2026

Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $631.68.

A number of brokerages recently weighed in on PRAX. Wall Street Zen downgraded shares of Praxis Precision Medicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Robert W. Baird set a $514.00 price target on Praxis Precision Medicines in a research note on Friday, August 7th. UBS Group initiated coverage on shares of Praxis Precision Medicines in a research note on Wednesday, October 14th. They set a “buy” rating and a $706.00 price objective for the company. The Goldman Sachs Group reissued a “buy” rating and issued a $575.00 target price (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Finally, BTIG Research restated a “buy” rating and issued a $826.00 price objective on shares of Praxis Precision Medicines in a research note on Monday.

Check Out Our Latest Research Report on Praxis Precision Medicines

Praxis Precision Medicines Price Performance

Shares of NASDAQ:PRAX opened at $324.76 on Tuesday. The company has a 50 day moving average of $290.44 and a 200-day moving average of $314.31. The stock has a market cap of $9.08 billion, a price-to-earnings ratio of -25.37 and a beta of 2.85. Praxis Precision Medicines has a one year low of $160.11 and a one year high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.54) by $0.31. Equities research analysts anticipate that Praxis Precision Medicines will post -13.98 earnings per share for the current year.

Hedge Funds Weigh In On Praxis Precision Medicines

Several large investors have recently modified their holdings of PRAX. Integrated Wealth Concepts LLC bought a new stake in shares of Praxis Precision Medicines during the 2nd quarter worth about $38,000. Parallel Advisors LLC grew its stake in Praxis Precision Medicines by 3,000.0% in the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock valued at $40,000 after buying an additional 120 shares during the last quarter. IFP Advisors Inc grew its stake in Praxis Precision Medicines by 632.0% in the 3rd quarter. IFP Advisors Inc now owns 183 shares of the company’s stock valued at $53,000 after buying an additional 158 shares during the last quarter. GAMMA Investing LLC raised its holdings in Praxis Precision Medicines by 10.3% in the 2nd quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after acquiring an additional 31 shares during the period. Finally, ABS Direct Equity Fund LLC bought a new position in Praxis Precision Medicines in the 1st quarter valued at about $135,000. 67.84% of the stock is owned by institutional investors.

Recent Praxis Precision Medicines Headlines

Investors following PRAX have been watching these headlines:

Positive Sentiment: At its Investor Day, Praxis outlined launch preparations for relutrigine and ulixacaltamide, with FDA target action dates of December 27, 2026, and January 29, 2027, respectively. The company also discussed its expanded pipeline, giving investors near-term regulatory milestones and potential commercial catalysts to watch. Investor Day announcement
Positive Sentiment: HC Wainwright raised its 2026 EPS estimate, projecting a smaller loss of $13.45 per share versus its prior $14.09 estimate, and maintained a Buy rating. BTIG and RBC Capital also issued Buy ratings, while RBC and Wedbush were reported as forecasting strong share-price appreciation. Analyst estimate update BTIG rating RBC rating
Negative Sentiment: Wells Fargo cut its price target on PRAX, a counterpoint to the recent Buy ratings and estimate increase. The available report does not specify the revised target or rationale. Wells Fargo price-target report

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.